Kodali Athri, Okoye Chiugo, Klein Dhadon, Mohamoud Iman, Olanisa Olawale O, Parab Panah, Chaudhary Priti, Mukhtar Sonia, Moradi Ali, Hamid Pousette
Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Medicine, Saint James School of Medicine, Park Ridge, USA.
Cureus. 2023 Aug 5;15(8):e42995. doi: 10.7759/cureus.42995. eCollection 2023 Aug.
Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases that have been associated with nonalcoholic fatty liver disease (NAFLD). This systematic review aimed to examine whether Crohn's disease confers a greater risk for nonalcoholic fatty liver disease compared to ulcerative colitis. A comprehensive search of electronic databases from January 2000 to May 2023 was conducted to identify observational studies investigating the association between Crohn's disease or ulcerative colitis and nonalcoholic fatty liver disease. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 checklist ensured transparent reporting, and the Newcastle-Ottawa Scale was used to assess study quality. Data synthesis revealed higher nonalcoholic fatty liver disease prevalence among Crohn's disease patients compared to ulcerative colitis patients across regions. Ten studies published between 2016 and 2022, encompassing a total of 4164 participants from three continents, were included in the review. The median proportion of Crohn's disease patients with nonalcoholic fatty liver disease was 37.22% (range: 10.95-53.80%), while it was 27.55% (range: 8.60-46.20%) for ulcerative colitis patients. Subgroup analysis by region confirmed CD's higher NAFLD risk. Median proportions for CD patients who developed NAFLD from North America, Europe, and Asia were 25.97% (range: 14.6-37.33%), 47.01% (range: 14.2-53.8%), and 20.78% (range: 10.95-30.6%), respectively, and the median proportion of persons with UC who developed NAFLD in studies from North America, Europe, and Asia were 17.28% (range: 8.6-25.96%), 37.70% (range: 25.64-46.20%), and 19.52% (range: 10.14-28.90%), respectively. Variations suggest differing mechanisms, disease features, and therapeutics. Transmural inflammation in Crohn's disease may increase metabolic abnormalities, including nonalcoholic fatty liver disease. Geographic differences in lifestyle, genetics, and environmental variables may also contribute. This review demonstrates that Crohn's disease patients face a higher nonalcoholic fatty liver disease risk than ulcerative colitis patients, emphasizing the need for early monitoring and prevention. Further studies are warranted to understand mechanisms and develop tailored management approaches.
克罗恩病(CD)和溃疡性结肠炎(UC)是与非酒精性脂肪性肝病(NAFLD)相关的炎症性肠病。本系统评价旨在研究与溃疡性结肠炎相比,克罗恩病是否会使非酒精性脂肪性肝病的风险更高。对2000年1月至2023年5月的电子数据库进行了全面检索,以确定调查克罗恩病或溃疡性结肠炎与非酒精性脂肪性肝病之间关联的观察性研究。系统评价和荟萃分析的首选报告项目(PRISMA)2020清单确保了透明报告,并使用纽卡斯尔-渥太华量表评估研究质量。数据综合显示,各地区克罗恩病患者的非酒精性脂肪性肝病患病率高于溃疡性结肠炎患者。本评价纳入了2016年至2022年间发表的10项研究,共涉及来自三大洲的4164名参与者。克罗恩病合并非酒精性脂肪性肝病患者的中位数比例为37.22%(范围:10.95 - 53.80%),而溃疡性结肠炎患者为27.55%(范围:8.60 - 46.20%)。按地区进行的亚组分析证实了克罗恩病患者非酒精性脂肪性肝病风险更高。北美、欧洲和亚洲患非酒精性脂肪性肝病的克罗恩病患者的中位数比例分别为25.97%(范围:14.6 - 37.33%)、47.01%(范围:14.2 - 53.8%)和20.78%(范围:10.95 - 30.6%),北美、欧洲和亚洲研究中患非酒精性脂肪性肝病的溃疡性结肠炎患者的中位数比例分别为17.28%(范围:8.6 - 25.96%)、37.70%(范围:25.64 - 46.20%)和19.52%(范围:10.14 - 28.90%)。差异表明机制、疾病特征和治疗方法不同。克罗恩病的透壁性炎症可能会增加代谢异常,包括非酒精性脂肪性肝病。生活方式、遗传学和环境变量的地理差异也可能起作用。本评价表明,克罗恩病患者面临的非酒精性脂肪性肝病风险高于溃疡性结肠炎患者,强调了早期监测和预防的必要性。有必要进一步研究以了解其机制并制定针对性的管理方法。